An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients With Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma
Skin Cancer (Non-Melanoma)
Stomach/ Gastric Cancer
18 Years and older, Male and Female
Ph 1 INBRX-105 (primary)
This is a first-in-human, open-label, nonrandomized, two-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and / or recommended Phase 2 dose (RP2D) of INBRX-105. INBRX-105, a next generation bispecific antibody, targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor. INBRX-105 provides immune checkpoint blockade of PD-L1 as well as conditional T cell co-stimulation through 4-1BB agonism for localized immune stimulation.